Module 4 Discussion Board 4 HCR 553
Module 4 Discussion Board 4 HCR 553
Selected Commitment from Section 9 of Form FDA 1572:
“I agree to inform any patients, or any persons used as controls, that the drugs are being used for investigational purposes and I will ensure that the requirements relating to obtaining informed consent in 21 CFR Part 50 and institutional review board (IRB) review and approval in 21 CFR Part 56 are met.”
Importance of the Protection of the Research Subject
This principle lies at the basis of ethical clinical research and the safety of human subjects. Informed consent is not just a formality, but a sign that individuals comprehend the nature of the study, such as the fact that the drug is investigational and not accepted for use by the general population. With this knowledge, subjects are able to make voluntary or autonomous decisions concerning their participation, in line with the ethical principles of the Belmont report, especially respect for persons and autonomy (Guidance, 2008). It also promotes transparency and trust between investigators and the subjects, which limits the aspect of exploitation. Furthermore, the process of informed consent safeguards patients against unanticipated outcomes since they are made to understand the possible risks, benefits, alternatives, and that they have the right to abandon the study without penalty at any point.
Investigator Activities and Responsibilities
As part of this commitment, the investigator must first ensure that both the clinical investigation and the informed consent document are reviewed and approved by an Institutional Review Board (IRB). The IRB must meet the regulatory standards outlined in 21 CFR Part 56 to safeguard the rights and welfare of research subjects. Before the enrolment of the subjects, a detailed description of the study should be presented in a language that the subjects can easily comprehend and devoid of undue influence as stipulated by 21 CFR 50.20 (Buchneva, 2025). The content of informed consent must meet the criteria under 21 CFR §50.25, including disclosures about the investigational nature of the drug, foreseeable risks or discomforts, and who to contact in the event of a research-related injury.
The researcher is obliged to keep signed and dated consent forms of every subject and reconsent them in case of significant new information. Any changes to the protocol or consent form must receive prior Institutional Review Board (IRB) approval unless changes are necessary to eliminate immediate hazards to subjects (Buchneva, 2025). Noncompliance may result in Food and Drug Administration (FDA) enforcement action and may compromise the ethical conduct of the research.
References
Buchneva, N. (2025, January 14). To sign or not to sign FDA Form 1572? Applied Clinical Trials. https://www.appliedclinicaltrialsonline.com/view/sign-or-not-sign-fda-form-1572
GUIDANCE, D. (2008). Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions-Statement of Investigator.
Module 4 Discussion Board 4 HCR 553
